• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

byJessie WillisandTeddy Guo
May 18, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Cabotegravir was shown to be superior to TDF-FTC in preventing HIV infection in women.

2. Both drugs were well tolerated and had similar adverse effects; however, there was a greater incidence of injection site reactions in the cabotegravir group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: HIV pre-exposure prophylaxis (PrEP), including oral tenofovir diphosphate plus emtricitabine (TDF-FTC), is available across sub-Saharan Africa. Unfortunately, many factors can contribute to poor compliance which may reduce the efficacy of these drugs. This phase 3 drug study evaluated the efficacy of a long-acting injection, cabotegravir, compared to daily TDF-FTC. Participants were randomly assigned 1:1 and received sham-controls of the non-assigned drug. The HIV incidence in the cabotegravir group was significantly lower than the TDF-FTC group. The study also demonstrated through drug screening blood tests that in the TDF-FTC group, daily drug compliance was less than 50%. Adverse events were similar between the two groups, except injection site reactions which were more frequent in the cabotegravir group. Limitations of this study include the lack of monitoring for oral daily pill taking; however, this provided an interesting finding in of itself. This study provides promising evidence for a safe, long-acting PrEP which could be used as an alternative to daily oral medication.

Click to read the study in the Lancet

Relevant Reading: HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery

RELATED REPORTS

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

Second-line TAF-based ART improves viral suppression in pediatric HIV

Alcohol use disorder may be associated with human immunodeficiency virus

In-Depth [randomized controlled trial]: HPTN 084 is a phase 3, randomized HIV prevention drug superiority trial across seven countries in sub-Saharan Africa. Eligible female participants were aged 18-45, at risk of HIV infection based on a risk score, reported at least two episodes of vaginal intercourse in the past 30 days, and consented to a long-acting contraceptive method. 3224 patients were randomized 1:1 to either cabotegravir injection with TDF-FTC placebo pill or TDF-FTC pill with cabotegravir injection placebo. The median age of participants was 25 years. The initial treatment plan was 5 weeks orally of both drugs to confirm cabotegravir tolerability before injection formulation. The injection was given at weeks 5, 9, and every 8 weeks thereafter. The following tail phase was open-label oral TDF-FTC daily for 48 weeks.

Participants were monitored and tested for HIV at each follow-up visit. The HIV incidence in the cabotegravir group (0.2 cases per 100 person-years [0.06-0.52]) was significantly lower than the TDF-FTC group (1.82 cases per 100 person-years [1.3-2.57]; hazard ratio 0.12, p<0.0001). A randomly selected 405 of the TDF-FTC group had tenofovir levels tested, 42.1% of blood samples demonstrated consistent daily use. Injection site reactions were more frequent in the cabotegravir group (38.0% vs. 10.7%) compared to placebo injection; however, they did not affect treatment.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Cabotegravirglobal healthHIVHIV/AIDShuman immunodeficiency virus (HIV)pre-exposure prophylaxis (PrEPTDF-FTCTenofovir
Previous Post

Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial

Next Post

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia

RelatedReports

Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

June 16, 2025
Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Second-line TAF-based ART improves viral suppression in pediatric HIV

June 4, 2025
Few high school students, young adults get HIV testing
Chronic Disease

Alcohol use disorder may be associated with human immunodeficiency virus

May 3, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Infectious Disease

Safety of investigational vaccines against human immunodeficiency virus

April 29, 2025
Next Post
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia

Obstetric scoring systems overestimate cases of severe sepsis

High pediatric sequential organ failure assessment (pSOFA) score may predict hospital mortality in emergency department setting

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
  • Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.